Research programme: microRNA therapeutics - Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - Regulus Therapeutics

Alternative Names: anti-miR-10b; anti-miR-122; miR-296; miR-34; miR-34a; miR-K12-11 (viral oncomir); miR-X; miRNA therapeutics - Regulus Therapeutics; Viral microRNAs - Regulus Therapeutics

Latest Information Update: 06 Mar 2014

Price : $50

At a glance

  • Originator California Institute of Technology/CalTech; Stanford University
  • Developer Cenix BioScience; Regulus Therapeutics
  • Class Antisense oligonucleotides; MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MicroRNA modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Diabetes mellitus; Heart failure; Hepatitis C; Immunological disorders; Metabolic syndrome; Viral infections

Most Recent Events

  • 06 Mar 2014 The lead candidate from this programme, RG 101, has entered clinical development
  • 12 Dec 2011 Regulus receives grant from Accelerate Brain Cancer Cure for microRNA therapeutics development in Glioblastoma multiforme
  • 09 Jun 2011 Preclinical pharmacodynamics data in Diabetes released by Regulus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top